Merial develops pharmaceutical drugs, biological vaccines, and wellness products for a range of animal health issues. Merial has pioneered a business model of outsourcing and contracting for services at different points in the value chain, thus providing access to complementary competencies outside the firm. Merial’s Pharma Discovery & Research department has implemented an advanced research informatics platform for sharing data and communicating with their worldwide network of research partners. Chemical synthesis partners in the USA and China upload data associated with the synthetic processes and Merial, as the sponsor, can rapidly review and provide feedback. CRO partners in the USA, France, and elsewhere run screens for Merial’s hit-to-lead/lead optimization/candidate drug molecules and the data is securely shared with Merial via the ScienceCloud. By orchestrating the research process, Merial owns the high-end of the drug discovery value chain. This has resulted in high productivity and tangible business outcomes including two drug candidates that have recently reached the clinical testing phase.